Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in CanadaAccesswire • Tuesday
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial ResultsAccesswire • 09/26/24
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024Accesswire • 09/19/24
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024Accesswire • 08/08/24
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health OperationsAccesswire • 08/06/24
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable TermsAccesswire • 06/18/24
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial ResultsAccesswire • 05/15/24
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024Accesswire • 05/08/24
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterAccesswire • 02/14/24
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024Accesswire • 02/07/24
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024Accesswire • 01/23/24
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive YearAccesswire • 11/08/23
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023Accesswire • 11/07/23
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementAccesswire • 10/26/23
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023Accesswire • 10/09/23
Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023Accesswire • 09/27/23